- Drug-drug interaction: Use with CYP2D6 and/or CYP3A inhibitors, strong CYP3A inducers, P-gp or CYP2D6 substrates
- Use of eliglustat in patients who are CYP2D6 indeterminate metabolizers or non-genotyped patients
- Off label use in Gaucher disease type 2 and 3